| P2093 | author name string | Crawford MH | |
| | Mulrow JP | |
| P2860 | cites work | Beneficial effects of hydralazine in severe mitral regurgitation | Q34266077 |
| | Treatment of chronic heart failure: a review of recent drug trials | Q34487586 |
| | Studies on the direct vasodilator effect of hydralazine in the isolated rabbit renal artery. | Q34662272 |
| | Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). | Q34682919 |
| | Studies on hydralazine; evidence for a peripheral site of action | Q35268506 |
| | Haemodynamic effects of hydralazine at rest and during exercise in patients with chronic heart failure | Q36774990 |
| | Vasodilator therapy of dilated cardiomyopathy | Q38951242 |
| | Haemodynamic effects of hydrallazine and of hydrallazine plus glyceryl trinitrate paste in heart failure | Q39578468 |
| | Hydralazine therapy in chronic congestive heart failure. Sustained central and regional hemodynamic responses | Q70491873 |
| | Prazosin and hydralazine in congestive heart failure. Regional hemodynamic effects in relation to dose | Q70817209 |
| | Metabolic assessment of exercise in chronic heart failure patients treated with short-term vasodilators | Q71131996 |
| | Rest and exercise hemodynamic effects of oral hydralazine in patients with coronary artery disease and left ventricular dysfunction | Q71140727 |
| | In vivo inhibition of thromboxane biosynthesis by hydralazine | Q71228945 |
| | Selective high-performance liquid chromatographic assays for hydralazine and its metabolites in plasma of man | Q71242240 |
| | Polymorphic acetylation of hydralazine | Q71295439 |
| | Kinetics of hydralazine and its main metabolites in slow and fast acetylators | Q71395579 |
| | Hydralazine kinetics after single and repeated oral doses | Q71395590 |
| | Positive inotropic effects of hydralazine in human subjects: comparison with prazosin in the setting of congestive heart failure | Q71424003 |
| | Effect of dose on acetylator phenotype distribution of hydralazine | Q71509189 |
| | Effect of intravenous dose on hydralazine kinetics after administration | Q71790207 |
| | Determination of hydralazine in human whole blood | Q71799313 |
| | Prostaglandin synthesis by vascular smooth muscle cells is stimulated by bradykinin, prazosin and hydralazine | Q72038419 |
| | Hydralazine and Plasma Renin Activity | Q72129003 |
| | Treatment of Acute and Chronic Congestive Heart Failure by Vasodilator-Afterload Reduction | Q72878091 |
| | HUMAN ACETYLATION POLYMORPHISM | Q76849232 |
| | Physiological disposition of hydralazine (1-hydrazinophthalazine) and a method for its determination in biological fluids | Q79024832 |
| | Determinants of systemic availability of oral hydralazine in heart failure | Q93630650 |
| | Hydralazine elimination in man | Q93748537 |
| | Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis | Q39931031 |
| | Vasodilator and inotropic therapy for severe chronic heart failure: Passion and skepticism | Q40091787 |
| | Prazosin Update A Review of its Pharmacological Properties and Therapeutic Use in Hypertension and Congestive Heart Failure | Q40135068 |
| | Vasodilator therapy of heart failure. Has the promissory note been paid? | Q40168627 |
| | Drug-induced systemic lupus erythematosus | Q40284808 |
| | Clinical pharmacokinetics of hydralazine | Q40333930 |
| | Medical intelligence drug therapy | Q40547744 |
| | Influence of adrenergic beta-receptor blockade on the acute cardiovascular effects of hydralazine | Q42076211 |
| | Influence of short-term oral hydralazine therapy on exercise hemodynamics in patients with severe chronic heart failure | Q42079736 |
| | Studies on the in vivo metabolism of hydralazine in the rat. | Q42241947 |
| | Effects of hydralazine on coronary blood flow and myocardial energetics in congestive heart failure | Q42263176 |
| | Vasodilator therapy | Q44459999 |
| | Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate | Q45336959 |
| | Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study | Q45337067 |
| | Fatty acid metabolism and cell proliferation. III. Effect of prostaglandin biosynthesis either from exogenous fatty acid or endogenous fatty acid release with hydralazine | Q46775193 |
| | Increased levels of prostaglandin-like material in the canine blood during arterial hypotension produced by hydralazine, dihydralazine and minoxidil | Q46942383 |
| | Effect of oral dose size on hydralazine kinetics and vasodepressor response | Q47234040 |
| | Importance of left ventricular chamber size in determining the response to hydralazine in severe chronic heart failure | Q47292772 |
| | Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine | Q47772528 |
| | Regional blood flow and cardiac responses to hydralazine. | Q51877755 |
| | Relative efficacy of vasodilator therapy in chronic congestive heart failure. Implications of randomized trials. | Q52562389 |
| | Mode of action of hydralazine on guinea pig atria. | Q52755631 |
| | Indomethacin attenuates the hypotensive action of hydralazine. | Q54428643 |
| | Vasodilator therapy for chronic congestive heart failure. | Q54439561 |
| | Role of vasodilators in the treatment of congestive heart failure. | Q54456284 |
| | Vasodilative effect of hydralazine in awake dogs: the roles of prostaglandins and the sympathetic nervous system. | Q54465962 |
| | Hydralazine therapy in severe chronic heart failure: Inability of radionuclide left ventricular ejection fraction measurement to predict the hemodynamic response | Q54489062 |
| | Determinants of circulatory response to intravenous hydralazine in congestive heart failure. | Q54492995 |
| | Effect of hydralazine on perfusion and metabolism in the leg during upright bicycle exercise in patients with heart failure. | Q54493017 |
| | Provocation of myocardial ischemic events during initiation of vasodilator therapy for severe chronic heart failure. Clinical and hemodynamic evaluation of 52 consecutive patients with ischemic cardiomyopathy. | Q54528779 |
| | Hydralazine in chronic CHF. | Q54542668 |
| | Oral hydralazine therapy for chronic refractory heart failure | Q54605468 |
| | High-pressure Liquid Chromatographic Assay for Hydralazine in Human Plasma | Q66973941 |
| | The determination of hydralazine in plasma by gas-liquid chromatography | Q67349733 |
| | Plasma levels of free and acid-labile hydralazine: effects of multiple dosing and of procainamide | Q67403371 |
| | Hemodynamic improvement after oral hydralazine in left ventricular failure: a comparison with nitroprusside infusion in 16 patients | Q67560065 |
| | Kinetics of hydralazine elimination | Q67575104 |
| | Enhancement of hydralazine bioavailability by food | Q67585403 |
| | Direct and reflex cardiostimulating effects of hydralazine | Q67592706 |
| | Cyclic AMP as a mediator of the relaxing action of papaverine, nitroglycerine, diazoxide and hydralazine in intestinal and vascular smooth muscle | Q68666874 |
| | Mechanism of direct cardiostimulating actions of hydralazine | Q68993795 |
| | Effect of vasodilators on survival in chronic congestive heart failure | Q69888190 |
| | Observation on the mechanism of renin release by hydralazine in hypertensive patients | Q69917637 |
| | Epidemiologic patterns, clinical evaluation, and long-term prognosis in chronic congestive heart failure | Q70009911 |
| | Updated diagnosis and management of congestive heart failure | Q70015985 |
| | Current indications for vasodilator therapy for left ventricular failure | Q70080715 |
| | Hydralazine versus placebo in CHF - preliminary results from a multicenter long term study in Sweden | Q70217114 |
| | Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo | Q70259924 |
| | Relation of hydralazine plasma concentration to dosage and hypotensive action | Q70374161 |
| P433 | issue | 2 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| | hydralazine | Q419987 |
| | congestive heart failure | Q19000661 |
| P304 | page(s) | 86-89 | |
| P577 | publication date | 1989-02-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure | |
| P478 | volume | 16 | |